445 results on '"Kunitoh H"'
Search Results
52. Genetic polymorphisms correlate with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX)
53. Differences in the toxicity and efficacy in phase I studies between cytotoxic and molecular-targeted therapies
54. Randomized phase II study of sequential carboplatin/paclitaxel (CP) and gefitinib (G) in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): Final results
55. Circulating tumor cell analysis in patients with non-small cell lung cancer
56. Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients
57. Effect of Platinum Combined with Irinotecan or Paclitaxel against Large Cell Neuroendocrine Carcinoma of the Lung
58. A randomized trial of intrapericardial (ip) bleomycin (BLM) after drainage for management of malignant pericardial effusion (MPE) in lung cancer patients (pts): Report of a Japan Clinical Oncology Group trial (JCOG 9811)
59. A phase I/II study of pemetrexed plus cisplatin in Japanese patients with malignant pleural mesothelioma
60. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
61. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
62. Association of polymorphisms in the MTH1 gene with small cell lung carcinoma risk
63. A randomized phase II study of sequential carboplatin/paclitaxel (CP) and gefitinib (G) in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): Preliminary results
64. Evaluation of epidermal growth factor receptor (EGFR) mutations as predictive and prognostic indicators in patients with adenocarcinoma of the lung treated with conventional chemotherapy
65. Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC)
66. EGFR mutations detected by high-resolution melting analysis (HRMA) as a predictor of response and survival in non-small cell lung cancer (NSCLC) patients treated with gefitinib
67. Dose intensive chemotherapy (Cx) in advanced thymoma: Initial report of Japan Clinical Oncology Group trials (JCOG 9605 and 9606)
68. Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC)
69. Genetic Variations and Haplotype Structures of theABCB1Gene in a Japanese Population: An Expanded Haplotype Block Covering the Distal Promoter Region, and Associated Ethnic Differences
70. Haplotype structures of the UGT1A gene complex in a Japanese population
71. O-190 Genetic, immunohistochemical, and clinical features associated with gefitinib sensitivity in patients with advanced non-small-cell lung cancer
72. O-155 Randomized phase III trial of carboplatin (Cb) or cisplatin (P) in combination with etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): Report of a Japan Clinical Oncology Group Trial (JCOG9702)
73. PD-050 A phase II trial of pre-operative chemoradiotherapy followedby surgical resection in Pancoast tumors: Report of a Japan Clinical Oncology Group trial (JCOG 9806)
74. O-043 A randomized phase II trial of pre-operative docetaxel and cisplatin (DP) or docetaxel alone (D) in clinical (c-) stage IB/II nonsmall cell lung cancer (NSCLC): Initial report of Japan Clinical Oncology Group trial (JCOG 0204)
75. Evaluation of epidermal growth factor receptor (EGFR) mutations and gene copy numbers as predictors of clinical outcomes in Japanese patients with recurrent non-small-cell lung cancer (NSCLC) receiving gefitinib
76. A phase II study of gefitinib monotherapy for chemotherapy-naive patients with non-small cell lung cancer
77. Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan
78. A randomized phase II trial of pre-operative docetaxel and cisplatin (DP) or docetaxel alone (D) in clinical (c-) stage IB/II non-small cell lung cancer (NSCLC): Initial report of Japan Clinical Oncology Group trial (JCOG 0204)
79. Dose intensive chemotherapy for limited-stage (LS) small cell lung cancer (SCLC): A phase II study
80. Induction of cytochrome P450 (CYP3A4) by gefitinib in non-small cell lung cancer (NSCLC) patients
81. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
82. Prognosis of lung cancer patients with high preoperative carcinoembryonic antigen (CEA) level: Are they surgical candidates
83. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients with chemotherapy-induced anemia
84. Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
85. Urgent need for a validated tumor response evaluation system for use in immunotherapy
86. 1079 A phase II trial of chemoradiotherapy followed by surgery in pancoast tumors: Initial report of the Japan Clinical Oncology Group trial (JCOG 9806)
87. Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
88. 1290P - Observational Study of Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (Egfr-Tki) in Activating Egfr Mutation-Positive (Egfrm+) Advanced or Recurrent Non-Small-Cell Lung Cancer (Nsclc) After Radiological Progression to First-Line Therapy with Egfr-Tki
89. 1254P - Prospective Observational Cohort Study of Second-Line Chemotherapy Administration After the First-Line Platinum-Based Chemotherapy for Patients with Advanced Nsclc in Japan (Sapphire Study): Update Analysis
90. A randomized phase III trial of docetaxel (D) and cisplatin (P) versus vindesine (V) and p in stage IV non small cell lung cancer (NSCLC)
91. A phase I trial of cisplatin (CDDP), docetaxel (DCT) and ifosfamide (IFX) in advanced non-small cell lung cancer (NSCLC)
92. Phase I study of docetaxel (DTX) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC)
93. Phase I and pharmacokinetic (PK) study of Nedaplatin (254-S) in elderly patients with advanced non-small cell lung cancer (NSCLC)
94. A phase II trial of low-dose docetaxel (DCT) 60 mg/m2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC)
95. Correlation between docetaxel clearance and estimated cytochrome P450 (CYP3A4) activity by urinary metabolite of exogenous cortisol for patients with advanced non-small cell lung cancer (NSCLC)
96. Lower recommended dose but not diminished efficacy obtained in elderly patients age 75 years or older in phase I study of cisplatin and docetaxel administered by 3 consecutive weekly infusions for advanced non-small cell lung cancer
97. Phase I study of weekly docetaxel (DTX) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for stage III non-small cell lung cancer (NSCLC)
98. Dose intensity of irinotecan (CPT) combined with weekly cisplatin (DDP) and etoposide (ETOP) in patients (pts) with metastatic lung cancer (LC): Phase I/II study JCOG 9507
99. Concurrent cisplatin/etoposide (PE) and twice-daily thoracic radiotherapy (BID TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited stage (LS) small cell lung cancer (SCLC)
100. The efficacy of MVP (mitomycin C, vindesine and cisplatin) regimen as a salvage chemotherapy for non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.